Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) (USD $)
In Thousands, except Share data
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated other comprehensive loss
Deficit Accumulated During the Development Stage
Total
Beginning Balance, Amount at Dec. 31, 2013 $ 10,108       $ 3,502    $ (12,335) $ (8,833)
Beginning Balance, Shares at Dec. 31, 2013 7,046 279 3,745        
Conversion of Series A Convertible Preferred Stock (7,046) 721           
Conversion of Series A Convertible Preferred Stock, Amount (10,108)    1 10,107       10,108
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Shares       115,907        
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Amount       116 (1,672)       (1,556)
Exercise of common stock options, Shares       175        
Exercise of common stock options, Amount          19       19
Stock-based compensation          11       11
Issuance of common stock and warrants in January 2014, Shares       5,500        
Issuance of common stock and warrants in January 2014, Amount       6 (6)         
Unrealized loss on marketable securities             (1,451)    (1,451)
Net loss                (372) (372)
Ending Balance, Amount at Mar. 31, 2014    $ 1 $ 122 $ 11,961 $ (1,451) $ (12,707) $ (2,074)
Ending Balance, Shares at Mar. 31, 2014    1,000 121,582